SVRA
Savara Inc (SVRA)
Healthcare • NASDAQ • $5.23+1.36%
Key Fundamentals
- Symbol
- SVRA
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $5.23
- Daily Change
- +1.36%
- Market Cap
- $1.07B
- Trailing P/E
- N/A
- Forward P/E
- -16.04
- 52W High
- $7.01
- 52W Low
- $1.89
- Analyst Target
- $10.81
- Dividend Yield
- N/A
- Beta
- 0.28
About Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Company websiteResearch SVRA on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.